• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Foghorn Therapeutics Inc.

    5/5/25 8:05:28 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FHTX alert in real time by email
    DEFA14A 1 d875647ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    FOGHORN THERAPEUTICS INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO    LOGO

     

     

    Foghorn Therapeutics Inc.

    Annual Meeting of Stockholders

     

    Tuesday, June 17, 2025 9:00 AM, Eastern Time

     

    Annual Meeting to be held live via the internet - please visit www.proxydocs.com/FHTX for more details.

     

    To attend the meeting online and/or participate, you must register at www.proxydocs.com/FHTX

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/FHTX

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 6, 2025.

     

    SEE REVERSE FOR FULL AGENDA

       LOGO

    Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO    Foghorn Therapeutics Inc. Annual Meeting of Stockholders

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

       FOR ON PROPOSALS 1 AND 2

     

     

     

    PROPOSAL

     

     

    1.    Elect Class II directors each for a three-year term   
       1.01 Stuart Duty   
       1.02 Neil J. Gallagher, M.D., PH.D.   
       1.03 Adrian Gottschalk   
       1.04 Ian F. Smith   
    2.    To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.   
    3.    Consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.   
    Get the next $FHTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FHTX

    DatePrice TargetRatingAnalyst
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    1/30/2025$10.00Buy
    B. Riley Securities
    9/3/2024$18.00Buy
    Jefferies
    8/19/2024$20.00Outperform
    Evercore ISI
    3/28/2023$10.00Buy
    BofA Securities
    1/5/2023$20.00Outperform
    BMO Capital Markets
    12/15/2021$23.00 → $26.00Overweight
    Morgan Stanley
    11/22/2021$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $FHTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Smith Ian F

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:29:40 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Parshall B Lynne

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:29:16 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mendelsohn Michael

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      6/17/25 4:28:43 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    SEC Filings

    See more
    • Foghorn Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

      6/17/25 4:01:55 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Foghorn Therapeutics Inc.

      10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)

      5/14/25 7:07:10 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Foghorn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)

      5/14/25 7:05:46 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseas

      5/22/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

      FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $220.6 million as of March 31, 2025, provides cash runway into 2027 CAMBRIDGE, Mass., May 14, 20

      5/14/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $FHTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

      Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

      4/23/25 8:16:18 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Foghorn Therapeutics with a new price target

      B. Riley Securities initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $10.00

      1/30/25 7:55:02 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Foghorn Therapeutics with a new price target

      Jefferies initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $18.00

      9/3/24 7:47:52 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FHTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

      5/1/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $FHTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Foghorn Therapeutics Inc.

      SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

      10/8/24 5:44:34 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Foghorn Therapeutics Inc.

      SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)

      9/20/24 6:00:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Foghorn Therapeutics Inc. (Amendment)

      SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

      6/10/24 9:48:22 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care